Nicox: partner receives approval in China

(CercleFinance.com) - Nicox announces that its exclusive Chinese licensing partner, Ocumension Therapeutics, has received approval for the marketing authorization application for ZERVIATE® (cetirizine ophthalmic solution), 0.
24% for ocular pruritus associated with allergic conjunctivitis in China. NB: cp +35%.

ZERVIATE is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC®. It is currently marketed in the US by Harrow, Nicox's exclusive partner in the US, for the treatment of ocular pruritus associated with allergic conjunctivitis.

The approval of ZERVIATE for marketing in China is a crucial milestone achieved by our partner, Ocumension Therapeutics. We have full confidence in their ability to orchestrate a rapid launch and leverage their strong commercial presence across the country to maximize market penetration." said Emmet Purtill, VP Business Development at Nicox.

This new launch will provide a new revenue stream for Nicox, which will receive royalties between 5% and 9% and milestone payments on net sales of ZERVIATE by Ocumension in China. Ocumension estimates peak sales of over $100m per year within 7 years.


Copyright (c) 2024 CercleFinance.com. All rights reserved.